Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Caterpillar, Corning, DexCom, Enphase Energy, First Solar, Invesco, 3M, Microsoft, Pfizer and Wynn Resorts.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
This week will be perhaps the biggest week of earnings season, with many major names reporting, including Amazon, Facebook, Ford and Starbucks.
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United States.…
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug…
Tuesday's top analyst upgrades and downgrades included AbbVie, CSX, Dominion Energy, JPMorgan, NXP Semiconductors, ONEOK, Pfizer, Square, United Parcel Service and WPX Energy.
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and…
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many…
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week trading highs and…
As of the most recently reported period, short sellers favored Pfizer, Exxon and Intel above all other Dow Jones industrial stocks, although two of them soon will be dropped from the index.
The Dow Jones industrial average changes look a bit strange, and the real effort behind those changes may simply be to juice the index higher in the future than due to the…
